Stay updated on Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.

Latest updates to the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no substantive content changes to the study details are visible in the screenshots.SummaryDifference0.1%

- Check20 days agoChange DetectedThis study was terminated early due to changes in melanoma treatment, with termination dated 2026-01-29. The recruitment status 'Active, not recruiting' was removed from the record.SummaryDifference0.5%

- Check27 days agoChange DetectedThe page now shows a glossary, adds a 'Last Update Submitted that Met QC Criteria' field, a 'No FEAR Act Data' indicator, and a 'Revision: v3.4.0' note. The previous 'Last Update Submitted that met QC Criteria' field, FEAR Act wording, and the older 'Revision: v3.3.4' version have been removed.SummaryDifference0.2%

- Check34 days agoChange DetectedThe label 'Last Update Posted (Estimated)' was changed to 'Last Update Posted'.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page revision label changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section with the Iowa site details. Removed the Iowa Locations block and the HHS Vulnerability Disclosure link, and updated the page revision to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.